Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Pfizer Inc.'s application for emergency use authorization in the US for its potential coronavirus vaccine will be not earlier than the third week of November.
The US pharmaceutical giant is one of several companies during final-stage clinical trials for potential coronavirus vaccines in the country.
According to Chairman and CEO Albert Bourla, Pfizer may find out later this month whether or not its vaccine can help prevent COVID-19 in at least a majority of those vaccinated.
if data from trials support the move, Pfizer will apply for emergency use authorization in the US after the safety milestone is achieved in the third week of November.
The US Food and Drug Administration requires companies to provide two months of safety data on half of the trial participants following the final dose of the vaccine.
Pfizer, which is developing the vaccine with Germany's BioNTech SE, has agreed to supply Japan with 120 million doses of a vaccine for 60 million people if the development efforts are successful.
Another American pharmaceutical firm Moderna Inc. revealed it wouldn't be ready to seek emergency use authorization before Nov. 25.
US President Donald Trump has been raising expectations that vaccines could be ready before the Nov. 3 presidential election.
